Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- GALT
- Price
- 1.35
- Stock movement up
- +0.06 (4.65%)
- Company name
- Galectin Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 84.73M
- Ent value
- 179.12M
- Price/Sales
- 1059.11
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -0.62%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 14.12%
- 1 year return
- -64.66%
- 3 year return
- -6.47%
- 5 year return
- -4.73%
- 10 year return
- -8.63%
Last updated: 2025-04-11
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
GALT does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1059.11 |
| Price to Book | - |
| EV to Sales | 2239.02 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 62.76M |
| EPS (TTM) | -0.72 |
| FCF per share (TTM) | -0.54 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 80.00K |
| Gross profit (TTM) | 53.00K |
| Operating income (TTM) | -39.57M |
| Net income (TTM) | -45.08M |
| EPS (TTM) | -0.72 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 66.25% |
| Operating margin (TTM) | -49457.50% |
| Profit margin (TTM) | -56346.25% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 27.06M |
| Net receivables | 0.00 |
| Total current assets | 28.67M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 28.97M |
| Accounts payable | 2.79M |
| Short/Current long term debt | 104.59M |
| Total current liabilities | 25.26M |
| Total liabilities | 121.45M |
| Shareholder's equity | -92.48M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -33.68M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -33.68M |
| Dividends paid (TTM) | 210.00K |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -155.59% |
| Return on Invested Capital | -372.38% |
| Cash Return on Invested Capital | -278.22% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.26 |
| Daily high | 1.42 |
| Daily low | 1.25 |
| Daily Volume | 192K |
| All-time high | 36.84 |
| 1y analyst estimate | 11.00 |
| Beta | 0.63 |
| EPS (TTM) | -0.72 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 13 May 2025 |
Downside potential
Loading...
Downside potential data
| GALT | S&P500 | |
| Current price drop from All-time high | -96.34% | -12.89% |
| Highest price drop | -99.02% | -56.47% |
| Date of highest drop | 17 Nov 2008 | 9 Mar 2009 |
| Avg drop from high | -81.78% | -11.07% |
| Avg time to new high | 354 days | 12 days |
| Max time to new high | 5430 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
84.73M
Marketcap category
Small-cap
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Employees
14
Investor relations
-
SEC filings
CEO
Harold H. Shlevin
Country
USA
City
Norcross
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page